There are more than 90% of pathogens cause infection via mucosal sites. But traditional intramuscular vaccines can not provide sufficient protection at mucosal sites, especially respiratory tract. Our technology provides safe and first line protection against pathogen invasion and reduces transmission between humans.
Outbreaks of infectious diseases pose a grave risk and burden formedical services and public health systems, both in the human cost of suffering and socioeconomic disruption.
Implementing proactive and effective surveillance and control measures for such outbreaks requires a comprehensive knowledge of the viruses circulating in both animals and humans.
Centre for Virology, Vaccinology and Therapeutics (CVVT) has been established to develop that critical base of knowledge and transform impactful research discoveries into practical applications to control and even prevent infectious diseases. Apart from the comprehensive knowledge of the viruses, CVVT aims to develop a novel vaccine platform for respiratory viruses, broad spectrum antivirals for prophylactic and therapeutic treatment, and highly-multiplex diagnostic tests for rapid detection.